Denali Therapeutics (DNLI) Debt to Equity (2022)
Denali Therapeutics (DNLI) reported Debt to Equity of $0.0 for Q4 2022, up 136.67% quarter-over-quarter from $0.0 in Q3 2022.
Denali Therapeutics (DNLI) Debt to Equity (2022) Analysis & Trends
Denali Therapeutics (DNLI) has 1 years of Debt to Equity data on file, last reported at $0.0 in Q4 2022.
- Debt to Equity for Q4 2022 came in at $0.0, changed N/A year-over-year; the trailing twelve-month figure through Dec 2022 was $0.0 (changed N/A YoY), and the FY2022 annual result was $0.0, changed N/A from the prior year.
- Debt to Equity climbed to $0.0 in Q4 2022 per DNLI's latest filing, from $0.0 in the prior quarter.
- Over five years, Debt to Equity peaked at $0.0 in Q4 2022 and troughed at $0.0 in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | - |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 0.32 |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | - |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Denali Therapeutics | 4.02 Bn | 4.02 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 0.00 |
| Sep 30, 2022 | 0.00 |
| Mar 31, 2022 | 0.00 |